Announcement of Amended License Agreement for OBP-1101(TelomeScan F35)

The Board of Oncolys BioPharma (“Oncolys”) is pleased to announce that it has resolved, at its board meeting on the 20 May 2016, to sign an amendment agreement with Wonik Cube Corp (“Wonik Cube”) to an existing OBP-1101 (TelomeScan F35) license contract in South Korea, in order to grant to Wonik Cube an exclusive manufacturing right of OBP-1101.

Oncolys and Wonik Cube entered into a License and Commercialization Agreement effective as of 1 December 2014 for exclusive rights of use of OBP-1101 (TelomeScan F35), an innovative gene-modified virus which detects circulating tumor cells (CTCs), as announced the same day. Being granted an OBP-1101 manufacturing right, Wonik Cube aims to manufacture the virus by itself, which both companies deem will consequently lead to promote and accelerate development of OBP-1101 to obtain a marketing authorization from authorities in South Korea.

In consideration of the additional right, Oncolys is entitled to receive a certain amount of royalty payment from Wonik Cube, of which details to remain undisclosed due to the agreement terms and Oncolys’ business development policies.

A related impact on OBP’s earnings prediction for the FY2016 is currently being evaluated.

About Wonik Cube
Company Name : WONIK CUBE CORP.
Address: 20, Pangyo-ro 255beon-gil, Bundang-gu, SEONGNAM, 13486, South Korea
Representative : Yeong Shin Oh, CEO
Establishment : May 1975
Total Paid-In Capital : KRW 1,370 million (approx. JPY 146.5million)
Main Business: Import, manufacturing and distribution of chemical products, etc.
Number of employees : 128 (as of 31/12/2015)
Earnings FY2015 :
   Sales : KRW 9,316 million (JPY 179.5bn)
   Operating Profit : KRW 2,558.9 million (JPY 49.3bn)
   Net Profit : KRW 2,171.6 million (JPY 41.8bn)
   (KRW1 = JPY19.27, as of 31/12/2015)